Total body irradiation (TBI) can cause short stature because of decreased growth hormone (GH) and skeletal abnormalities. To evaluate the plasma concentrations of markers of bone formation (osteocalcin and procollagen type 1 amino-terminal propeptide, P1NP) and resorption (carboxy-terminal telopeptide, CTX), in patients (n ¼ 65) who had been given TBI at 6.6±0.4 years were evaluated at 9.8 ± 0.4 years. Patients given single 10 Gy or fractionated 12 Gy TBI had similar characteristics, except that plasma insulin-like growth factor (IGF-1) was lower in those given a single 10 Gy. Seven had lower osteocalcin and two had higher CTX than controls. Bone markers (as zs) were positively correlated (osteocalcin with P1NP, q ¼ 0.42, P ¼ 0.0007; osteocalcin with CTX, q ¼ 0.3, Po0.02), but not P1NP with CTX. Plasma osteocalcin and CTX were also positively correlated with plasma IGF-1, but not with growth rate during the first year on GH (n ¼ 28). Adult height was À2.5 ± 0.2 s.d.s. (n ¼ 49). Those irradiated when young (P ¼ 0.0002) or given single TBI lost more height between TBI and adult height. Most TBI patients had normal bone formation and resorption markers. Thus, impaired bone turnover is probably not the cause of their short stature and poor response to GH.
Introduction
The total body irradiation (TBI) used before hematopoietic cell transplantation (HCT) can cause short stature: hypothalamic-pituitary irradiation may decrease growth hormone (GH) secretion, whereas body irradiation may cause skeletal abnormalities. The main radiation-induced abnormalities are osteochondroma, abnormal metaphyses, scoliosis and enchondroma. 1 Some of them may be responsible for resistance to insulin-like growth factor (IGF) 1 and poor growth in response to GH therapy. 2 Thus, the GH peak after a stimulation test and the plasma IGF-1 concentration of each patient vary greatly from low to normal, even for a given patient, and are not correlated between them or with the height loss after TBI. 3 Hence, the diagnosis of GH deficiency and the indications for GH treatment are particularly difficult, and this difficulty may be increased by the initial malignant disease.
The height loss is reported to be greater in boys than in girls 4 and in those patients who underwent cranial irradiation before TBI, 5 or were given single rather than fractionated TBI. 4 We found that the age at TBI is the major determinant of height loss between the height at TBI and the adult height. 3 This loss was greater than 2 standard deviation score (s.d.s.) in 13/17 of the boys and 10/10 of the girls who underwent TBI before they were 8-years old. Fletcher et al.
1 studied patients given 12-14.4 Gy TBI, and found that those aged less than 8 years at TBI had more severe skeletal abnormalities than those aged 12-19 years. These data suggest that the relationship between the age at TBI and the height loss is mainly mediated by the bone damage.
We have here examined the skeletal abnormalities induced by TBI and its factors by evaluating the plasma concentrations of markers of bone formation (osteocalcin and procollagen type 1 amino-terminal propeptide, P1NP) and resorption (carboxy-terminal telopeptide, CTX). These concentrations were compared with the normal data for age-matched controls, to the characteristics of the patients, and to their growth rate during the first year of GH treatment.
Patients and methods

Patients
This retrospective study included 65 patients (40 boys) followed by one of us (R Brauner) after TBI. Another 34 patients seen during the same period were excluded because they had factors other than conditioning for HCT that might have interfered with their growth (additional cranial irradiation (n ¼ 18), long-term corticosteroid therapy (n ¼ 5) or chronic complications of HCT (n ¼ 7)) or no sample available for assaying the bone markers (n ¼ 4).
All were given HCT before their 11th year (girls) or 13th year (boys), and were evaluated for their GH secretion. The conditioning protocol for HCT included chemotherapy 2 and TBI (10 Gy single dose) with an 18 mV linear accelerator at 4.2 cGy/min (n ¼ 16) or 12 Gy (6 fractions of 2 Gy within 3 consecutive days) with a 5.5 mV linear accelerator at 50 cGy/min (n ¼ 49).
Their ages were 6.6 ± 0.4 (1.3-13) years at TBI, 9.8 ± 0.4 (2.8-14.8) years when the bone markers were evaluated, and 15.3 ± 0.4 (2.7-23.5) years at the last evaluation. Forty-nine of them reached their adult height.
Protocol
Informed consent for the evaluations and treatments was obtained from the children's parents. The Ethics Review Committee (Comite´de Protection des Personnes Ile de France III) stated that 'this research was found to conform to generally accepted scientific principles and research ethical standards and to be in conformity with the laws and regulations of the country where the research experiment was performed'.
Fasting patients were evaluated in a single morning; we measured their height, weight, pubertal stage, plasma IGF-1, thyroid stimulating hormone, free thyroxin concentrations and GH pharmacological stimulation test, using sequential arginine insulin as first and ornithine or glucagon as second stimulus. Aliquots of plasma were frozen at À20 1C and used to measure the bone markers. They were collected before GH and sex steroid treatments, 3.2±0.3 years after TBI.
The patients with high thyroid stimulating hormone concentrations were given thyroxin (50-100 mg/m 2 per day). The patients of pubertal age who had uncompensated sex steroid deficiency were given oral ethinyl estradiol (2 mg per day) at the age of around 12 years for six girls or testosterone heptylate (25 mg i.m. every 14 days) at 14 years for one boy. The doses were increased to adult levels at the end of growth and the girls were also given cyclical progestin. Twenty eight patients (43%) were given GH (0.2-0.23 mg/kg/w) because of a GH peak o10 ng/ml and a total height loss from HCT of 41 s.d.
Methods
Height and body mass index (BMI, weight in kg/height in meters squared) data are expressed as s.d.s. 6, 7 Target heights were calculated from parental heights. 8 Adult height was considered to be reached when the growth was o1 cm during the preceding year and a bone age 415 years in girls and 16 years in boys.
Three height losses were calculated: the differences between the height at TBI and the height at bone marker evaluation, between the height at TBI and the adult height, and between the adult and target heights, expressed as s.d.s.
Serum IGF-1 was measured with an immunoradiometric assay (IGF-I RIA-CT, Schering-Cis Bio, Gif sur Yvette, France). Serum P1NP, osteocalcin and CTX were measured with recently developed automated immunochemiluminescent sandwich assays on the Elecsys platform (Roche Diagnostics, Meylan, France). Intra-and inter-assay coefficients of variation for serum measurements were for osteocalcin-3.3 and 3.8% at a concentration of 13.7 ng/ ml, 1.4 and 1.8% at 68.3 ng/ml; for P1NP-2.1 and 2.4% at a concentration of 271 ng/ml, 2.9 and 3.7% at 799 ng/ml; for CTX-1.8 and 4.3% at a concentration of 3022 pmol/l, 1.0 and 1.6% at 27 022 pmol/l. The normal concentrations were established in our laboratory, and IGF-1, 9 osteocalcin, P1NP and CTX are expressed as Z-score (zs) to overcome variations with age.
The results are expressed as means±s.d. Groups were compared with a Mann-Whitney U-test. Correlations were analyzed using Spearman's test.
Results
Characteristics before GH treatment
The patients given single 10 Gy or fractionated 12 Gy TBI had similar characteristics, except that the plasma IGF-1 concentrations of the patients given single 10 Gy were lower than in those given fractionated 12 Gy (Table 1 ). The characteristics of the boys and girls were also similar.
Compared with controls, seven patients had lower osteocalcin and two had greater CTX concentrations ( Figure 1) . The others had normal-for-age osteocalcin, P1NP and CTX concentrations. The characteristics of these seven were similar to those of the others, including the initial disease, age at TBI, BMI and the IGF-1 concentrations.
At bone marker evaluation, 36 patients had high thyroid stimulating hormone concentrations, 4 of them had free thyroxin concentrations at the lower limit of normal, and 4 girls had uncompensated sex steroid deficiency. One of these had low plasma concentrations of osteocalcin and IGF-1.
Growth on GH treatment and adult height
The growth rates during the first year of GH treatment of the patients given single 10 Gy and those given fractionated 12 Gy (Table 1) TBI were similar. The mean adult height for the whole population was-2.5±0.2 s.d.s. It was similar in both groups, as was the difference between the adult and target heights; but the height losses between the height at TBI and the height at bone markers evaluation, and between the height at TBI and the adult height were significantly greater in the patients given single 10 Gy irradiation than in those given fractionated 12 Gy TBI.
Correlations
The bone markers (expressed as zs) were positively correlated between themselves (osteocalcin with P1NP, r ¼ 0.42, P ¼ 0.0007; osteocalcin with CTX, r ¼ 0.3, Po0.02), but not P1NP with CTX. The plasma concentrations of osteocalcin and CTX were also positively correlated with that of plasma IGF-1, whereas that of P1NP was not (Figure 1 ).
They were not correlated with the age at TBI, the interval between TBI and evaluation, the GH peak, BMI, height losses (s.d.s.) between the height at TBI and the height at bone marker evaluation, the height at TBI and the adult height, the adult and target heights or the growth rate during the first year of GH treatment (cm). This growth rate was not correlated with the GH peak or the plasma IGF-1 concentration before treatment. The height loss between the height at TBI and the adult height was greater in those who were irradiated young (P ¼ 0.0002).
Discussion
The majority of the patients evaluated 3.2 years after TBI had normal plasma concentrations of osteocalcin, P1NP and CTX, regardless of the age at TBI, the irradiation protocol used, the interval between TBI and evaluation, the GH peak or the height losses. The plasma osteocalcin was positively correlated with the P1NP and CTX concentrations, as were osteocalcin and CTX with the plasma IGF-1 concentrations. None of them was correlated with the growth response to GH treatment.
Factors influencing bone marker concentrations
All the patients were given HCT before they were of pubertal age and conditioned by TBI. There was no factor other than conditioning for HCT, like long-term corticosteroid therapy and/or chronic complications of HCT that might have interfered with their growth, plasma IGF-1 or bone marker concentrations. They all had plasma thyroxin concentrations within the normal range at evaluation. Four girls suffered from a lack of sex steroids, one of them had a low osteocalcin and IGF-1 concentrations. We found no difference in the bone marker concentrations according to the initial disease, but the 3/7 patients with low osteocalcin represent 21% of the neuroblastomas.
We found no correlation between the plasma bone marker concentrations and the age at TBI, despite the fact that the age at TBI is the major determinant of height loss 3 and skeletal abnormalities. 1 There is also no correlation between these concentrations and the BMI or GH peak, although the osteocalcin and CTX are positively correlated with the plasma IGF-1 concentration. The patients given a single 10 Gy irradiation have lower IGF-1, greater height losses between the height at TBI and the height at bone marker evaluation, and between the height at TBI and the adult height, than those given fractionated 12 Gy TBI, despite having similar BMIs, GH peaks and percentages of GH deficiency. Others have found significant correlations between the decrease in bone mineral density (BMD) and IGF-1 in adults given HCT (see below). It has been suggested that high-dose chemotherapy damages the osteoprogenitor cells. However, this does not explain the height loss, as there is no loss after conditioning by chemotherapy alone. 10 Bone markers and GH The markers of bone formation and resorption are either low 11 or normal 12 at baseline in patients with GH deficiency (reviewed in Ohlsson et al.
13
). As these concentrations increase significantly on GH treatment, 12 with a strong corrrelation between them and the changes in growth rate, it has been suggested that markers of bone formation and/or bone resorption should be assessed 3 months after the start of GH therapy in GH deficient children, and their values used to predict the growth response to GH. [14] [15] [16] We have shown 17 that lower basal plasma P1NP concentrations predict a better growth response by idiopathic short stature children to GH treatment during the first year, and that greater increases in its concentrations after 3-6 months of GH treatment may also predict a better growth response in them and in the children with intrauterine growth retardation. This study finds no correlation between the plasma bone markers and IGF-1 concentrations or GH peak, and the growth rate during the first year of GH treatment. We have no explanation for this difference from reported data, except that TBI-induced skeletal lesions might have modified the growth response.
Published data on the bone markers after HCT The results of this study, obtained 3.2 years after HCT, are concordant with the data reported for adults, showing that the bone marker concentrations decrease after HCT and return to normal 1 year after HCT. Adults suffer from significant bone loss during the first year after HCT, with decreases in the BMD in the lumbar spine and proximal femur of up to 5-10%. 18 The lumbar BMD decrease as the glucocorticoid and cyclosporine doses increase and with the occurrence of graft-versus-host disease. 19 The plasma concentrations of osteocalcin and IGF-1 decrease during the first 3 weeks after HCT and return to baseline after 1 year, whereas the concentration of collagen I carboxy-terminal telopeptide (ICTP), a marker of resorption, does just the opposite. 19 The percentage changes in the BMD at the proximal femur from the baseline and 1 year and the serum IGF-1 concentrations 3 weeks and 3 months after HCT are significantly correlated. 19 The authors suggest that the factors influencing the post HCT bone loss are the hypogonadism induced by TBI and/or high-dose chemotherapy, reduced bone formation caused by glucocorticoids and cyclosporine, underproduction of IGF-1 because of direct damage to the osteoprogenitor cells, and the decreased GH secretion caused by TBI-induced hypothalamic-pituitary injury. However, the authors suggest that the low IGF-1 is not because of GH deficiency, as it was similar in the patients given TBI, and in those who were not. Instead, they suggest gonadal dysfunction, myeloablation-related osteoprogenitor cell injury and poor nutrition after HCT. The same authors 20 cultivated bone marrow stromal cells from bone marrow donors and bone marrow recipients and found that the differentiation of bone marrow stromal cells into osteoblasts was impaired after HCT. They suggest that this might contribute to the bone loss.
There is one published study on bone markers after HCT in adolescents with thalassemia. 21 It showed that a severe BMD deficit is common in transfused patients, but that it is lower in those given HCT. These latter had significantly higher plasma osteocalcin concentrations than did the transfused patients. The time after transplantation and the concentration of bone-specific alkaline phosphatase, a marker of bone formation, were associated with the spine BMD in these HCT patients.
Nysom et al. 22 found that the whole-body bone mass was only slightly reduced and that the size-adjusted bone mass content was normal 8 years after TBI for childhood leukemia or lymphoma. Halton et al. 23 evaluated children given chemotherapy for acute lymphoblastic leukemia: plasma osteocalcin was subnormal at diagnosis in 73% of them, but increased to normal after 6 months of treatment, whereas the urinary concentration of cross-link N-telopeptide, a marker of bone resorption, was normal at diagnosis and became elevated in 58% of the children by the end of therapy.
Conclusion
Markers of bone formation and resorption are normal in most patients given TBI regardless of the conditioning protocol. These findings suggest that the short stature and poor response to GH of these patients are not because of impaired bone turn over. Thus, none of the three markers we studied can be used to detect bone lesions or to predict the response to GH treatment.
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